App-Quantinova.ai

Killer-cell Inmunoglobulin-like Receptor (KIR) genes as a predictor of response to the anti-HER therapy in solid tumors.

Cristina Morales-Estevez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

Trastuzumab

Routine pharmacogenomic testing of lung cancer in Taiwan.

Kang-Yi Su - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Dermatux: Phase IV trial of C-FOLFIRI in 1st-line metastatic colorectal cancer receiving a pre-defined skin care.

Carl Christoph Schimanski - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

L-leucovorin

Distribution of CDH13, CDH1, MGMT and PTEN promoter methylation and KRAS, BRAF and EGFR mutation in colorectal cancer.

Garry Mahon - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

First-line panitumumab plus docetaxel and cisplatin in advanced gastric or gastroesophageal junction adenocarcinoma: Results of a phase II trial (SPIGA).

Guillermo Alfonso Quintero Aldana - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

panitumumab

Predictive biomarkers to ramucirumab in Asian metastatic gastric cancer patients: Circulating angiogenic factors of VEGFR2 and neurophilin as predictive to ramucirumab efficacy in Asain recurrent/metatatic gastric cancer patients.

Seungtaek Lim - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Ramucirumab

Contribution of eukaryotic translation initiation factor 3B to the pathogenesis of hepatocellular carcinoma via targeting EGFR and ZAK.

Jian-Feng Zheng - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Varlitinib to demonstrate anti-tumour efficacy in patient-derived hepatocellular carcinoma xenograft models.

Chih-Yi Hsieh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Prognostic and predictive value of mRNA expression of mTOR and VEGF pathway members in metastatic renal cell carcinoma (mRCC).

Dmitry Nosov - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Everolimus

Early clinical results of a phase II trial evaluating neoadjuvant chemotherapy followed by chemoradiation and maintenance gefitinib in locally advanced cervical cancer.

Rony Benson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cervical cancer

Carboplatin

Evaluation of genomic alterations in primary small cell carcinoma of the ovary (SCCO).

George Yaghmour - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroendocrine tumors

N/A

Basal subtype of head and neck cancer to define response to EGFR inhibitor treatment.

Konrad Friedrich Klinghammer - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

Adrucil injection

Development of biomarkers to guide the clinical development of tarloxotinib bromide, a hypoxia-activated irreversible EGFR/HER2 inhibitor.

Adam V Patterson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

Tarloxotinib bromide

Validity of clinical information for a novel cancer care quality program.

John Barron - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Are the gene expression profiles of Hispanic patients with lung cancer living in the US different from Hispanics living abroad?

Luis E. Raez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Actionable biomarkers in a non-small cell lung cancer (NSCLC) clinical pathway (CP).

Peter G. Ellis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Mutation analysis in 35 cases of newly diagnosed therapy-related acute myeloid leukemia (AML) by next-generation sequencing (NGS): A clinico-pathologic correlation.

Parsa Hodjat - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

TP53

Correlation among the biomarkers for oral anti-cancer agents in lung adenocarcinoma.

Nariyasu Nakashima - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

EGFR mutations in tumor tissue and blood collected from lung cancer patients by Insight Onco NGS technique.

Jin-Hyoung Kang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Neoadjuvant gefitinib for stage II-IIIA NSCLC with activating EGFR mutation (NCT01833572): an open-label, single-arm, phase II study.

Ranxia Gong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

gefitinib

Filters

3441 Abstracts